RCUS
USDArcus Biosciences Inc. Common Stock
Echtzeitkurs
Kursdiagramm
Schlüsselkennzahlen
Marktkennzahlen
Eröffnung
$19.700
Hoch
$20.500
Tief
$19.691
Volumen
0.41M
Unternehmensfundamentaldaten
Marktkapitalisierung
2.4B
Branche
Biotechnologie
Land
United States
Handelsstatistiken
Durchschnittliches Volumen
1.18M
Börse
NYQ
Währung
USD
52-Wochen-Spanne
Ähnliche Nachrichten
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune
Goldman Sachs Maintains Neutral on Arcus Biosciences, Raises Price Target to $16
Goldman Sachs analyst Salveen Richter maintains Arcus Biosciences with a Neutral and raises the price target from $14 to $16.
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $56
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences with a Buy and raises the price target from $54 to $56.
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $28
HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences with a Buy and raises the price target from $24 to $28.
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line kidney
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $54
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences with a Buy and raises the price target from $47 to $54.
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
First overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study will be presented on October 18 at the European Society for Medical Oncology (ESMO) 2025 Congress These data support the ongoing
Ähnliche Aktien
CPS
Cooper-Standard Holdings Inc.
MFAN
MFA Financial Inc. 8.875% Senior Notes due 2029
WHF
WhiteHorse Finance Inc.
CBH
Virtus Convertible & Income 2024 Target Term Fund Common Shares of Beneficial Interest
PWP
Perella Weinberg Partners
Bleiben Sie auf dem Laufenden
Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.